Nutraceutical Therapy for Patients Suffering from Myalgic Encephalomyelitis or Chronic Fatigue Syndrome (ME or CFS), Post-Covid Syndrome (PCoS), or Alzheimer Disease (AD) - Abstract
In the present observational prospective open-label study the effect was evaluated of treating 113 patients suffering from myalgic encephalomyelitis/ chronic fatigue syndrome (ME/CFS) or from post-COVID syndrome (PCoS, also called long-COVID) with either the nutraceutical QALY® plus sodiumdichloroacetate and meldonium, or with infusions containing magnesium-sulphate plus multivitamins, or with glutathione plus stem cells. Overall 86% of patients reported a variable degree of decreased fatigue after 4 to 6 weeks, with no significant difference between the two modes of treatment. In addition, in 2 patients with evolutive age-related Alzheimer’s disease (AD) receiving oral therapy together with the extract of Hericium echinaceus, mental deterioration could be halted for 48 and 72 months respectively. Taking into account the limitations of the present preliminary study it is suggested that complementary treatment may be considered as add-on to conventional therapy in ME/CFS or PCoS patients, as well as in patients suffering from age-related AD.